Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

Thomas Bachelot ,A-C Hardy Bessard,Julien Grenier ,Pietrina Cottu ,J.p Jacquin ,Laurence Venat-Bouvet ,Florence Dalenc ,Djelila Allouache ,Marc Debled ,David Cameron ,J-L Canon ,Étienne Brain ,Judith Bliss ,Francesco Del Piano ,Murray Brunt ,Sylvie Giacchetti ,Mario Campone ,Jérôme Lemonnier ,Sylvie Chabaud ,Fabrice André

doi:10.1016/j.annonc.2021.02.003

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

Thomas Bachelot , A-C Hardy Bessard + Show 18 more

Open Access

PDF Available

https://doi.org/10.1016/j.annonc.2021.02.003

Copy DOI

Export

Save

Cite

Journal: Annals of Oncology	Publication Date: Feb 19, 2021
Citations: 10	License type: elsevier-specific: oa user license

Affiliation: Centre Léon Bérard, Institut Sainte Catherine, Institute Curie, Institute Cancer De La Loire Lucien Neuwirth, Hôpital Dupuytren, Institut Claudius Regaud, Centre François Baclesse, Institut Bergonié, Western General Hospital, Grand Charleroi Hospital, Ethypharm (France), Institute of Cancer Research, Royal Stoke University Hospital, Hôpital Saint-Louis, Institut de Cancérologie de l'Ouest, UniCancer Group, Institut Gustave Roussy

#Everolimus In Combination #Early Breast Cancer #High Risk Early Stage Breast #Efficacy Of Everolimus In Patients #High Risk Early Stage #Efficacy Of Everolimus #Everolimus In Patients #High Risk Early Breast Cancer #High-risk HR #Hormone Therapy

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

Everolimus (EVE) in combination with hormone therapy (HT) has been shown to improve progression free survival for advanced HR+/HER2- breast cancer (BC). The double blind randomized UNIRAD trial aimed to investigate the benefit of adjuvant EVE in combination with standard adjuvant HT versus HT alone for women with high-risk HR+/HER2- early BC.

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer